TACSTD2 and neoplasm: Sacituzumab govetican is an antibody–drug conjugate (ADC) consisting of a monoclonal antibody targeting the tumour-associated calcium signal transducer 2 (trophoblast cell-surface antigen 2; Trop-2) protein, a surface protein commonly overexpressed in TNBC, and SN-38, the active metabolite of irinotecan.